Education
About Us
Working with TipRanks
Follow Us
General Cannabis Corp (CANN)
OTHER OTC:CANN
Top Page
General Cannabis
(OTC:CANN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.00
▼(-100.00% Downside)
The overall stock score is primarily impacted by significant financial challenges, including high leverage and negative profitability. While there is some positive short-term momentum, the stock appears overbought, and valuation metrics are unattractive with a negative P/E ratio. These factors collectively result in a low overall score.
General Cannabis (CANN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.31M
Dividend YieldN/A
Average Volume (3M)152.58K
Price to Earnings (P/E)―
Beta (1Y)-0.67
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees91
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding108,746,520
10 Day Avg. Volume152,002
30 Day Avg. Volume152,580
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.64
Price to Sales (P/S)0.14
P/FCF Ratio-2.78
Enterprise Value/Market Cap4.76
Enterprise Value/Revenue1.85
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda29.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
General Cannabis Business Overview & Revenue Model
Company DescriptionTrees Corporation provides products and services to the regulated cannabis industry and non-cannabis customers in the United States. The company operates through Retail and Cultivation segments. It operates a licensed 17,000 square foot light deprivation greenhouse cultivation facility; and a retail dispensary store in Englewood, Colorado, as well as two retail stores in Portland, Oregon. The company was formerly known as General Cannabis Corp. and changed its name to Trees Corporation in June 2022. Trees Corporation was incorporated in 2013 and is headquartered in Denver, Colorado.
How the Company Makes MoneyGeneral Cannabis generates revenue through multiple channels. Its primary revenue streams include consulting services, where the company offers strategic guidance and operational support to cannabis businesses. Additionally, the company earns income from real estate services, leveraging its properties to cater to cannabis operations. The sale of cannabis-related products and branding services also contributes to its revenue. Strategic partnerships with various cannabis operators enhance its market presence and create additional revenue opportunities, while the overall growth in the legal cannabis market adds to its financial performance.
General Cannabis Financial Statement Overview
Summary
General Cannabis faces significant financial challenges, with declining revenues, high leverage, and negative profitability. The company needs to address operational inefficiencies and improve its financial stability to enhance its financial health.Income Statement
General Cannabis has shown declining revenue growth with a negative trend in net profit margins, indicating challenges in profitability. The gross profit margin is moderate, but the EBIT and EBITDA margins are negative, reflecting operational inefficiencies.30
Negative
Balance Sheet
The company has a high debt-to-equity ratio, indicating significant leverage, which poses financial risk. Negative stockholders' equity and poor return on equity further highlight financial instability.20
Very Negative
Cash Flow
Operating and free cash flows are negative, although there is some improvement in free cash flow growth. The ratios of cash flow to net income suggest cash flow challenges relative to earnings.25
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.66M | 18.14M | 13.44M | 5.93M | 7.12M |
| Gross Profit | 5.45M | 6.57M | 4.87M | 1.49M | 1.65M |
| EBITDA | 900.75K | -1.64M | -2.84M | -6.12M | -6.19M |
| Net Income | -3.48M | -7.08M | -9.48M | -8.87M | -7.68M |
Balance Sheet | |||||
| Total Assets | 20.76M | 23.25M | 31.69M | 22.02M | 8.52M |
| Cash, Cash Equivalents and Short-Term Investments | 214.33K | 969.68K | 2.58M | 2.05M | 750.22K |
| Total Debt | 17.31M | 17.88M | 22.54M | 10.15M | 4.76M |
| Total Liabilities | 23.84M | 23.10M | 25.29M | 12.42M | 7.52M |
| Stockholders Equity | -3.07M | 148.16K | 6.41M | 9.61M | 1.00M |
Cash Flow | |||||
| Free Cash Flow | -704.76K | -1.43M | -2.11M | -2.98M | -5.32M |
| Operating Cash Flow | -654.15K | -1.13M | -2.05M | -2.65M | -5.00M |
| Investing Cash Flow | -50.60K | -304.42K | -1.95M | -978.74K | 1.11M |
| Financing Cash Flow | -50.59K | -184.25K | 4.53M | 4.93M | 4.42M |
General Cannabis Technical Analysis
Positive
0.05
Price Trends
0.04
Positive
0.03
Positive
0.03
Positive
Market Momentum
<0.01
Negative
61.34
Neutral
77.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANN, the sentiment is Positive. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.04, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.34 is Neutral, neither overbought nor oversold. The STOCH value of 77.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CANN.
General Cannabis Risk Analysis
General Cannabis disclosed 33 risk factors in its most recent earnings report. General Cannabis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
General Cannabis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $22.50M | -0.82 | -60.76% | ― | -18.05% | 33.87% | |
48 Neutral | $5.31M | -1.52 | ― | ― | ― | ― | |
48 Neutral | $517.58M | ― | -2.64% | ― | -4.21% | 7.78% | |
31 Underperform | $5.78M | -0.12 | -708.34% | ― | ― | 51.27% |
* Healthcare Sector Average
CANN
General Cannabis
0.05
0.00
0.00%
AYTU
Aytu BioScience
2.30
0.14
6.48%
ORGO
Organogenesis Holdings
4.11
1.31
46.79%
KALA
Kala Pharmaceuticals
0.78
-6.02
-88.53%
SXTC
China SXT Pharmaceuticals
1.34
-3.26
-70.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.